April 27, 2017 - La Jolla Pharmaceutical Co. (NASDAQ:LJPC) has filed a financial statement reporting Liabilities of $9,758,000 USD.
Related News Stories
Today we will discuss Abeona Therapeutics (ABEO) after the company announced that it has nabbed a Rare Pediatric Disease designation from the FDA for ABO-202 for the treatment of CLN1 disease, which is a rare inherited disorder of the nervous system. (159-2)
For investors who have watched the staggering moves in bitcoin and somehow feel that they missed the bus, they were reminded last week when the cryptocurrency dropped back almost 35% just how insanely volatile the trade can be. While it may yet to prove to be the new standard for payment in the future, that sure won’t be the case anytime soon. (252-14)
How to find special situation and event-driven opportunities, merger arb and distressed investing are topics discussed and Value Detective shares a bullish thesis on PICO Holdings and Cision. (24-1)
The market potential for La Jolla's primary asset, a treatment for hypo-tension in Septic Shock patients, is severely overestimated in my opinion. (250-8)
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (418-2)